Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 26;117(2):1129–1138. doi: 10.1073/pnas.1910856117

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published under the PNAS license.

PMC Copyright notice

Fig. 5. — Impact of combinatorial CCX872/anti-PD-1 treatment on peripheral and tumor myeloid cell populations. (A) Flow-cytometric analysis of Ly6C⁺ vs. Ly6G⁺ events in KR158 tumor isolates (Upper) and bone marrow cell populations (Lower) from vehicle-treated (n = 6) and CCX872-treated (n = 6) animals. Drug treatment resulted in a reduction (P = 0.038) of Ly6C^hi events within tumors and an increase (P = 0.028) in bone marrow. (B) Flow-cytometric analysis of Ly6C⁺ vs. Ly6G⁺ events in 005 GSC tumor isolates (Upper) and bone marrow cell populations (Lower) from vehicle-treated (n = 6) and CCX872-treated (n = 5) animals. Drug treatment resulted in a reduction (P = 0.015) in Ly6C^hi events within tumors and an increase (P = 0.028) in bone marrow. (C) Flow-cytometric analysis of tumor isolates from KR158 tumor-bearing Ccr2^RFP/WT/Cx3cr1^GFP/WT mice depicting CCR2⁺ vs. CX3CR1⁺ (Upper) and Ly6C⁺ vs. Ly6G⁺ events (Lower) from vehicle-treated (n = 5) and CCX872-treated (n = 7) animals. Drug treatment resulted in a significant reduction of CCR2⁺ (P = 0.024) and CCR2⁺/CX3CR1⁺ (P = 0.032) events. The lower graphs report a reduction (P = 0.004) in Ly6C^hi events within tumors. (D) Flow-cytometric analysis of tumor isolates from 005 GSC tumor-bearing Ccr2^RFP/WT/Cx3cr1^GFP/WT mice depicting CCR2⁺ vs. CX3CR1⁺ (Upper) and Ly6C⁺ vs. Ly6G⁺ events (Lower) from vehicle-treated (n = 6) and CCX872-treated (n = 6) animals. Drug treatment resulted in a reduction of CCR2⁺ (P = 0.003), CX3CR1⁺ (P = 0.003), and CCR2⁺/CX3CR1⁺ (P = 0.0419) events. The lower graphs report a reduction (P = 0.020) in Ly6C^hi events within tumors. Representative plots are shown throughout. *P < 0.05; **P < 0.01.